share_log

HC Wainwright & Co. Maintains Buy on Theravance Biopharma, Lowers Price Target to $15

Benzinga ·  Aug 6, 2024 15:02  · Ratings

HC Wainwright & Co. analyst Douglas Tsao maintains Theravance Biopharma (NASDAQ:TBPH) with a Buy and lowers the price target from $20 to $15.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment